Stefanie Zschaebitz

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, Arun Azad, Joan Carles et al. · Journal of Clinical Oncology · 2023 · 46 citations

Medicine, Oncology, Pharmacology +16

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Stefan A. Koerber, Katharina Sprute, Clemens Kratochwil et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 33 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

Georg Martin Haag, Niels Halama, Christoph Springfeld et al. · Journal of Clinical Oncology · 2020 · 30 citations

Medicine, Immunology, Pharmacology +17

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Neeraj Agarwal, Arun Azad, Joan Carles et al. · Journal of Clinical Oncology · 2025 · 27 citations

Medicine, Oncology, Pharmacotherapy +15

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Karim Fizazi, Arun Azad, Nobuaki Matsubara et al. · Journal of Clinical Oncology · 2023 · 17 citations

Medicine, Oncology, Pharmacology +7